POLR3G and breast cancer: The fact that we found these results in clinical data as well as in vitro in the KO cell line model and in vivo in the mouse model suggests that POLR3G/RPC32α expression contributes to the regulation of FOXA1 and AR expression, thereby potentially affecting luminal or basal cell identities in breast cancer.